Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigation of ITGB3 Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer

25 Dec 2024

Abstract excerpt

HER2-positive breast cancer has an aggressive tumour progression among breast cancers characterized by the overexpression of HER2. Trastuzumab is an FDA-approved drug and has significantly improved outcomes for patients; however, drug resistance remains a major challenge. Tumour heterogeneity, describing genetic, epigenetic, and phenotypic differences within and between tumours, complicates tumour treatment and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion Molecules Research
Share to HER2/EGFR in Cancer Research
Share to TGF-β signaling in diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39857240
DOI: 10.3390/biology14010009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Investigation of ITGB3 Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast CancerPMID 39857240Read ↗

Targeting ITGβ3 to Overcome Trastuzumab Resistance through Epithelial–Mesenchymal Transition Regulation in HER2-Positive Breast CancerSemantic proximity Read ↗

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast CancerSemantic proximity Read ↗

mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer.Semantic proximity Read ↗

A Bioinformatic Investigation into the Role of ITGB1 in Cancer Prognosis and Therapeutic ResistanceSemantic proximity Read ↗

Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients.Semantic proximity Read ↗

Concurrent Mutations Associated With Trastuzumab-resistance Revealed by Single Cell SequencingSemantic proximity Read ↗

Metabolic Alterations driven by PFKFB3 upregulation confer Resistance to Trastuzumab in HER2-Positive Breast CancerSemantic proximity Read ↗

Concurrent mutations associated with trastuzumab-resistance revealed by single cell sequencing.Semantic proximity Read ↗

Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancerSemantic proximity Read ↗

Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapySemantic proximity Read ↗

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancerSemantic proximity Read ↗

A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.